Aurobindo pharma Limited has announced its earnings call schedule to discuss the third quarter financial results for FY26. The pharmaceutical company informed stock exchanges about the upcoming investor interaction as part of its regulatory disclosure requirements.

Earnings Call Details

The company has scheduled the earnings call with specific timing and access arrangements for analysts and investors.

Regulatory Compliance

The announcement was made pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary B. Adi Reddy signed the communication digitally on February 2, 2026, ensuring compliance with regulatory disclosure norms.

The notification was simultaneously sent to both major stock exchanges where the company is listed:

• National Stock Exchange of India Limited (Company Code: AUROPHARMA)
• BSE Limited (Company Code: 524804)

Access and Participation

Investors and analysts interested in participating in the earnings call need to pre-register through the provided Zoom link. The company has indicated that the earnings presentation will be made available on its official website following the results announcement.

The call will focus on discussing the unaudited financial results for the third quarter and nine months period ended December 31, 2025, providing stakeholders with insights into the company's operational and financial performance during this period.

Company Information

Aurobindo Pharma Limited operates with its corporate office located at Galaxy, Floors 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad. The company maintains its commitment to regulatory transparency through timely disclosure of material information to investors and market participants.

Aurobindo Pharma Limited has issued another clarification to stock exchanges regarding significant volume movement in its shares, maintaining its position that the activity remains linked to government policy changes affecting the pharmaceutical sector. The company provided the latest clarification on February 2, 2026, responding to fresh queries from the National Stock Exchange of India Limited dated February 1, 2026.

Updated Exchange Communication

The pharmaceutical company reiterated its stance on the trading volume increase, emphasizing that the movement continues to be market-driven following the government's Minimum Import Price notification. The latest communication reinforces the company's previous explanation while addressing renewed exchange scrutiny.

Government MIP Policy Impact

The company continues to highlight the connection between the share volume movement and the Government of India's notification imposing Minimum Import Price on specific pharmaceutical compounds. The policy covers imports intended for domestic consumption and directly impacts products manufactured by the company's subsidiary.

Media Coverage and Public Domain Information

Aurobindo Pharma specifically addressed media coverage surrounding the potential impact of the MIP policy, noting that all relevant information was already available through official government channels. The company emphasized that details were published on the Government's DGFT website, making the information publicly accessible to all market participants.

The pharmaceutical company clarified that since the MIP notification represents general industry policy rather than company-specific developments, no separate disclosure was required under regulatory guidelines. This distinction helps explain why the volume movement appears to be driven by market interpretation rather than undisclosed corporate information.

Regulatory Compliance Reaffirmation

In its latest communication, the company reaffirmed its commitment to maintaining continuous compliance with disclosure obligations. Aurobindo Pharma emphasized its track record of making timely and adequate disclosures of all material events and information in strict adherence to SEBI regulations.

The company confirmed that as of the latest clarification date, there remains no other information or pending announcements that could impact the price or volume movement of its securities, providing continued transparency to investors and market participants.

Source: